Editor | Lang Ming
Unlike the founder behind the innovative pharmaceutical company born in Montana, the actual controller of Junshi Bio has no biomedical background.
On June165438+1October 12, the "Animal House Office" published an article entitled "Jianghu is the way of the world", pointing out the main products and research and development strength of Junshi Bio.
165438+1October 13 in the morning, Junshi Bio quickly responded that it was "seriously inconsistent with the objective facts".
But it is worth noting that in this article, it is also pointed out that "the team and the company are led by a father and son without any biological background."
At present, the controlling shareholders and actual controllers of Junshi Bio are Xiong Fengxiang and Xiong Jun. As of September 30, 2020, the father and son held 4.72% of the shares of Junshi Bio 1 13 in June, with a closing price of 7220 yuan per share at noon, and their net worth reached 93.43 billion yuan.
Judging from academic qualifications, it has nothing to do with biomedicine. According to the prospectus, Xiong Jun received a bachelor's degree in investment management from Zhongnan University of Economics and Law on 1996 and a master's degree in business administration from the Chinese University of Hong Kong in 2007. Xiong Fengxiang 1982 graduated from Wuhan Institute of Electric Power, majoring in power generation and distribution, with a college degree.
Judging from Xiong Jun's work experience, he is better at capital operation. From 2004 to 2006, he worked as a research assistant and fund manager in Guolian Fund Management Company. Since the establishment of Shanghai Baoying Asset Management Company in 2007, he has been the chairman. 20 13-20 15 served as the chairman of Shanghai zhonghe medicine.
Zhonghe Medicine has something to do with Shi Jun Biology. It was founded in 2008, and it is a biomedical company mainly engaged in the research and development and industrialization of monoclonal antibody new drugs, which is consistent with the research direction of Junshi Biology. 20 14, 1, the new third board was listed.
During his tenure as director of Xiong Junzhong Pharmaceutical, Zhang Zhuobing and Shan Jikuan, directors and core technicians of Zhonghe Pharmaceutical, jointly invested RMB 654.38+00000 to establish Junshi Bio. After that, Xiong Fengxiang and Xiong Jun became the actual controllers of Junshi Bio through share agreement transfer.
In other words, after some operation, He Zhong Medicine and Junshi Bio have a * * * same "father". The actual controllers of Junshi Bio are Xiong Fengxiang and Xiong Jun, the controlling shareholder of Zhonghe Medicine is Xiong Jun, and the chairmen of both companies are Xiong Jun. Some shareholders of Zhonghe Medicine are also shareholders of Junshi Bio.
In the end, it became a natural thing for the two families to come together. On 20 15, Junshi Bio completed the share reform and listed on the New Third Board, and on 20 16, it completed the merger and acquisition of Zhonghe Pharmaceutical. Since then, Junshi Bio has started to flourish in the capital market, with 20 18 listed on the Hong Kong Stock Exchange and 2020 listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange.
In addition to Xiong Jun's operation in the capital market, Xiong Jun's father Xiong Fengxiang is also a man with a business mind. Although in the prospectus, Xiong Fengxiang retired from June 2007 1 1 and served as the supervisor of Guangzhou Gubu Electronic Technology Co., Ltd. from February 65438, 2008.
According to Tianyancha, the chairman of Hunan Fengxiang Liquor Chain Store Co., Ltd. (referred to as Hunan Fengxiang Liquor Store) is Xiong Fengxiang, which owns 10 companies, most of which are also related to the liquor industry. According to the company relationship, Xiong Fengxiang, chairman of Hunan Fengxiang Liquor Company, is inextricably linked with Xiong Jun.